Alvotech Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
1,460
- Stock Symbol
-
ALVO
- Investments
-
5
- Share Price
-
$4.18
- (As of Friday Closing)
Alvotech General Information
Description
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Contact Information
Website
www.alvotech.comCorporate Office
- 9, rue de Bitbourg
- Luxembourg
- Luxembourg
Corporate Office
- 9, rue de Bitbourg
- Luxembourg
- Luxembourg
Alvotech Timeline
Alvotech Stock Performance
As of 13-Nov-2026, Alvotech’s stock price is $4.18. Its current market cap is $1.5B with 357M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.18 | $4.67 | $2.94 - $6.53 | $1.5B | 357M | 1.12M | -$0.62 |
Alvotech Financials Summary
As of 30-Jun-2026, Alvotech has a trailing 12-month revenue of $492M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,707,261 | 2,837,827 | 5,056,954 | 4,000,660 |
| Revenue | 491,954 | 586,321 | 489,682 | 91,434 |
| EBITDA | 148,541 | 308,304 | (36,892) | (498,495) |
| Net Income | (179,590) | 27,919 | (231,864) | (551,731) |
| Total Assets | 1,587,468 | 1,487,099 | 1,221,400 | 950,090 |
| Total Debt | 1,451,785 | 1,449,145 | 1,190,236 | 1,075,474 |
Alvotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alvotech Comparisons
Industry
Financing
Details
Alvotech Competitors (50)
One of Alvotech’s 50 competitors is GlobeImmune, a Formerly VC-backed company based in Louisville, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GlobeImmune | Formerly VC-backed | Louisville, CO | ||||
| Samsung Bioepis | Corporate Backed or Acquired | Incheon, South Korea | ||||
| InterveXion Therapeutics | Corporation | Little Rock, AR | ||||
| mAbxience | Corporate Backed or Acquired | Madrid, Spain | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India |
Alvotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alvotech Patents
Alvotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025256338-A1 | High concentration aflibercept formulations | Pending | 16-Apr-2024 | ||
| WO-2025219484-A1 | High concentration aflibercept formulations | Pending | 16-Apr-2024 | ||
| AU-2024232412-A1 | Denosumab formulation | Pending | 03-Mar-2023 | ||
| EP-4676959-A1 | Denosumab formulation | Pending | 03-Mar-2023 | ||
| US-20260242496-A1 | Denosumab formulation | Pending | 03-Mar-2023 | C07K16/2875 |
Alvotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alvotech Investments & Acquisitions (5)
Alvotech’s most recent deal was a Merger/Acquisition with Ivers-Lee. The deal was made on 09-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ivers-Lee | 09-Jul-2025 | Merger/Acquisition | Other Containers and Packaging | ||
| Xbrane Biopharma (R&D Operations and Biosimilar Candidate XB003 in Stockholm, Sweden) | 04-Jun-2025 | Merger/Acquisition | Drug Delivery | ||
| Oaktree Acquisition II | 16-Jun-2022 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| CAHT | 01-Mar-2019 | Joint Venture | Drug Discovery | ||
| Alvotech Hannover | 18-May-2016 | Merger/Acquisition | Biotechnology |
Alvotech ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.14 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Alvotech Exits (1)
Alvotech’s most recent exit was on 18-May-2016 from Alvotech Hannover. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Alvotech Hannover | 18-May-2016 | Completed |
|
Alvotech Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Alvotech Hannover | Juelich, Germany | 2011 | |
| Ivers-Lee | Burgdorf, Switzerland | 1947 |
Alvotech FAQs
-
When was Alvotech founded?
Alvotech was founded in 2013.
-
Where is Alvotech headquartered?
Alvotech is headquartered in Luxembourg, Luxembourg.
-
What is the size of Alvotech?
Alvotech has 1,460 total employees.
-
What industry is Alvotech in?
Alvotech’s primary industry is Pharmaceuticals.
-
Is Alvotech a private or public company?
Alvotech is a Public company.
-
What is Alvotech’s stock symbol?
The ticker symbol for Alvotech is ALVO.
-
What is the current stock price of Alvotech?
As of 13-Nov-2026 the stock price of Alvotech is $4.18.
-
What is the current market cap of Alvotech?
The current market capitalization of Alvotech is $1.5B.
-
What is Alvotech’s current revenue?
The trailing twelve month revenue for Alvotech is $492M.
-
Who are Alvotech’s competitors?
GlobeImmune, Samsung Bioepis, InterveXion Therapeutics, mAbxience, and Biocon are some of the 50 competitors of Alvotech.
-
What is Alvotech’s annual earnings per share (EPS)?
Alvotech’s EPS for 12 months was -$0.62.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
